- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04471129
Non-invasive Ventilation and High-speed Oxygen Therapy Effects on Heart Function - HiFlow-Heart Study (HiFlow-Heart)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators propose to carry out a prospective randomized cross-over prospective physiological study comparing, Non-Invasive Ventilation and High Flow Oxygen Therapy in patients with chronic uncompensated heart failure. This stable population would make it possible to easily study variations in a physiological parameter without any added risk for the patient, but with all the pathophysiological parameters transposable to the situation of decompensated heart failure.
Indeed, it is accepted that the existence of heart failure with decreased left ventricular ejection fraction (LVEF) (< 40%) exposes patients to a high risk of congestive cardiac decompensation due to the associated presence of diastolic dysfunction1.
The study will be conducted using an alternating design, where a patient receives the two treatments one after the other ("cross-over"), because the alternating design, compared to the two parallel arm design, reduces the number of patients needed to show a given difference between High Flow Oxygen Therapy and Non-Invasive Ventilation at equal power, if there is neither an order-of-prescription effect ("period") nor a residual effect of the first treatment on the second treatment ("carry-over"). In order to avoid a residual effect on changes in pressure or oxygenation, a wash-out period on conventional oxygen therapy (O2C) should be set between the two treatments (High Flow Oxygen Therapy and Non-Invasive Ventilation) administered to the same patient.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elisabeth Surlemont, Dr
- Phone Number: +33232881705
- Email: Elisabeth.Surlemont@chu-rouen.fr
Study Contact Backup
- Name: Emmanuel Besnier, Dr
- Phone Number: +332888283
- Email: Emmanuel.Besnier@chu-rouen.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Major patient
- Patient who has undergone cardiac surgery with extracorporeal circulation for more than 24 hours and has been extubated for at least 6 hours.
- Pre-operative heart failure with left ventricular ejection fraction < 40%.
- Invasive monitoring by pulmonary arterial catheter (Swan-Ganz) with transpulmonary thermodilution and by radial arterial catheter intended for use in the intra- and post-operative monitoring of the patient.
- Treatment with conventional oxygen therapy (O2C) without an increase in O2 flow for more than 30 minuts, without signs of hypoxemia (SpO292%)
- Stable hemodynamic parameters: no changes in hemodynamic parameters (arterial pressures and pulmonary and cardiac index) by more than 10% over the 30 minutes prior to inclusion and no increase in cardiotropic medication for at least 30 minutes.
- Patient with an oxygenation rate ≤ 6L
- For women of child-bearing age: negative pregnancy test at inclusion
- Person who has read and understood the information letter and signed the consent form
- Affiliation to a social security scheme
Exclusion Criteria:
- Contraindication to the use of NIV or HFO
- Patient with orotracheal intubation or tracheotomy
- Renal failure with hemodialysis or hemofiltration
- Uncontrolled state of shock (PAS<90 mmHg and/or cardiac index<1.8 L/min/m² and/or norepinephrine>0.2 μg/kg/min and/or dobutamine>10 μg/kg/min)
Acute respiratory failure as defined by :
- clinical signs: respiratory rate >35/min, signs of struggle, SpO2<92% on O2C
- indication for treatment with NIV or HFO at the discretion of the clinician
- oxygen dependency requiring O2C>6L/min O2C flow at the oxygen mask
- Chronic advanced respiratory disease
- Chronic treatment with NIV or CPAP at home
- Non-operated aortic or mitral insufficiency ≥ II/IV
- Administration of loop diuretics within 3 hours prior to inclusion for intravenous forms and within 6 hours for oral forms.
- Presence of altered consciousness defined by a Glasgow score < 15/15 or cognitive dysfunction defined by a CAM-ICU score > 0/4
- Pregnant or parturient or nursing woman or proven lack of effective contraception
- Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection / subtutorship or guardianship
- Person participating in another trial / having participated in another trial that may interfere with the procedures that are the subject of the research within a 4-week time frame
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: High-Flow Oxygen Therapy, followed by Non-Invasive Ventilation
oxygenation first by High-Flow Oxygen Therapy, then by O2C, then by Non-Invasive Ventilation
|
High-flow oxygen therapy + O2C + Non invasive ventilation
|
OTHER: Non-Invasive Ventilation, followed by High-Flow Oxygen Therapy
oxygenation first by Non-Invasive Ventilation, then by O2C, then by High-Flow Oxygen Therapy
|
Non invasive ventilation + O2C + High-flow oxygen therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
High-Flow Oxygen Therapy and Non Invasive Ventilation on left ventricular filling pressures
Time Frame: Day 1
|
Difference between High-Flow Oxygen Therapy and Non Invasive Ventilation on left ventricular filling pressures as assessed by the occluded pulmonary artery occlusion pressure (in mmHg) measured by Swan-Ganz pulmonary artery catheterization
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison between High-Flow Oxygen Therapy and Non-Invasive ventilation w.r.t. ventricular function
Time Frame: Day 1
|
Arterial pressure [mmHg] measured by Swan-Ganz catheter
|
Day 1
|
Comparison between High-Flow Oxygen Therapy and Non-Invasive ventilation w.r.t. arterial oxygenation
Time Frame: Day 1
|
Arterial oxygen saturation, SaO2 [%], measured by Swan-Ganz catheter
|
Day 1
|
Comparison between High-Flow Oxygen Therapy and Non-Invasive ventilation w.r.t. change in pulmonary volume
Time Frame: Day 1
|
End-expiratory lung impedance (mean of 3 measures), measured by PulmoVista (Draeger, Germany)
|
Day 1
|
Patient comfort
Time Frame: Day 1
|
Patient's evaluation of comfort on Visual Analog Scale (10 points)
|
Day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/0400/HP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
AquaPass Medical Ltd.CompletedChronic Heart FailureIsrael
-
Zensun Sci. & Tech. Co., Ltd.Terminated
Clinical Trials on HFO/O2C/NIV
-
University Hospital, ToulouseCompleted
-
RWTH Aachen UniversityCompletedProximal Humeral FracturesGermany
-
RWTH Aachen UniversityWithdrawnMicrocirculation of the Caput FemorisGermany
-
Istituti Clinici Scientifici Maugeri SpAFisher and Paykel Healthcare; Azienda Ospedaliera Ospedale Maggiore di Crema; University of Modena and Reggio Emilia and other collaboratorsCompleted
-
University of ZurichMayo Clinic; McGill University; University of Michigan; UMC Utrecht; University of... and other collaboratorsEnrolling by invitationEpilepsy IntractableSwitzerland
-
University of California, Los AngelesCompletedPediatric Epilepsy | Epilepsy Surgery | High Frequency OscillationUnited States
-
Trakya UniversityCompleted
-
Rennes University HospitalRecruitingChronic Obstructive Pulmonary Disease (COPD) | Obesity With a BMI Greater Than 30 | Acute Respiratory Distress in Adult Intensive CareFrance
-
Vejle HospitalCompletedRespiratory Insufficiency | Acute Respiratory InsufficiencyDenmark
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Politecnico di MilanoCompletedPrematurity | Neonatal Respiratory Distress SyndromeItaly